Frontiers in Pharmacology (Nov 2016)

BIASED AGONISM OF THREE DIFFERENT CANNABINOID RECEPTOR AGONISTS IN MOUSE BRAIN CORTEX

  • Rebeca Diez-Alarcia,
  • Rebeca Diez-Alarcia,
  • Inés Ibarra-Lecue,
  • Ángela Patricia López-Cardona,
  • Ángela Patricia López-Cardona,
  • Javier Meana,
  • Javier Meana,
  • Alfonso Gutierrez-Adán,
  • Luis F Callado,
  • Luis F Callado,
  • Ekaitz Agirregoitia,
  • Leyre Urigüen,
  • Leyre Urigüen

DOI
https://doi.org/10.3389/fphar.2016.00415
Journal volume & issue
Vol. 7

Abstract

Read online

Cannabinoid receptors are able to couple to different families of G-proteins when activated by an agonist drug. It has been suggested that different intracellular responses may be activated depending on the ligand. The goal of the present study was to characterize the pattern of G protein subunit stimulation triggered by three different cannabinoid ligands, THC, WIN55212-2 and ACEA in mouse brain cortex.Stimulation of the [35S]GTPS binding coupled to specific immunoprecipitation with antibodies against different subtypes of G proteins (Gαi1, Gαi2, Gαi3, Gαo, Gαz, Gαs, Gαq/11, and Gα12/13), in the presence of Δ9-THC, WIN55212-2 and ACEA (submaximal concentration 10 µM) was determined by Scintillation Proximity Assay (SPA) technique in mouse cortex of wild type, CB1 knock-out, CB2 knock-out and CB1/CB2 double knock-out mice. Results show that, in mouse brain cortex, cannabinoid agonists are able to significantly stimulate not only the classical inhibitory Gαi/o subunits but also other G subunits like Gαz, Gαq/11, and Gα12/13. Moreover, the specific pattern of G protein subunit activation is different depending on the ligand. In conclusion, our results demonstrate that, in mice brain native tissue, different exogenous cannabinoid ligands are able to selectively activate different inhibitory and non-inhibitory Gα protein subtypes, through the activation of CB1 and/or CB2 receptors. Results of the present study may help to understand the specific molecular pathways involved in the pharmacological effects of cannabinoid-derived drugs.

Keywords